FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.
What happened
In March 2026, FDA reviewed Altru Telehealth's website and observed that it offered compounded semaglutide and tirzepatide products. FDA found website claims that the compounded drugs were FDA-approved or offered the same results as brand-name drugs, and that the compounding pharmacies were "FDA approved."
What FDA found
The website claimed compounded semaglutide and tirzepatide products were FDA-approved or otherwise evaluated for safety and effectiveness when compounded drugs are not FDA-approved.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website claimed compounded semaglutide and tirzepatide offer the same results as brand-name drugs such as Ozempic, Mounjaro, and Wegovy at a fraction of the cost, which FDA says is false or misleading.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website claimed its compounding pharmacies are "FDA approved," but FDA does not approve or license compounding pharmacies or outsourcing facilities.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The false or misleading claims cause the compounded drug products to be misbranded and introduced into interstate commerce, which is prohibited.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Altru Telehealth to respond within 15 business days with corrective steps, supporting documents, the entities that produce the compounded products, a sample of labeling, and changes or removal of false or misleading website claims.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies whose products are marketed online
- marketing and compliance teams for online pharmacy websites
This is a summary. Read the original letter on fda.gov.